$CALA 11:24 AM EST, 11/30/2016 (MT Newswires) --
Post# of 23063
Posted On: 11/30/2016 11:25:55 AM
$CALA
11:24 AM EST, 11/30/2016 (MT Newswires) -- Calithera Biosciences (CALA) shares were higher 4% on Wednesday as the company said clinical data demonstrate the clinical activity, tolerability and mechanism of action of CB-839 in patients with renal cell carcinoma.
"CB-839 is the first tumor metabolism drug to target a pathway that starves cancer cells by directly depriving them of a key nutrient," CEO said Susan Molineaux said.
As of Oct. 25, the company said 15 renal cell carcinoma patients were treated and evaluable for response, including 12 clear cell patients, and three papillary patients. It said 93% have disease control; one patient has a partial response, one patient has progressive disease, and 13 patients have stable disease.
The median progression free survival is 8.5 months and for the majority of patients, their time on therapy is longer than their time on treatment in their prior therapy, Calithera said.
Price: 3.48, Change: +0.13, Percent Change: +3.73
http://www.mtnewswires.com Copyright © 2016 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
11:24 AM EST, 11/30/2016 (MT Newswires) -- Calithera Biosciences (CALA) shares were higher 4% on Wednesday as the company said clinical data demonstrate the clinical activity, tolerability and mechanism of action of CB-839 in patients with renal cell carcinoma.
"CB-839 is the first tumor metabolism drug to target a pathway that starves cancer cells by directly depriving them of a key nutrient," CEO said Susan Molineaux said.
As of Oct. 25, the company said 15 renal cell carcinoma patients were treated and evaluable for response, including 12 clear cell patients, and three papillary patients. It said 93% have disease control; one patient has a partial response, one patient has progressive disease, and 13 patients have stable disease.
The median progression free survival is 8.5 months and for the majority of patients, their time on therapy is longer than their time on treatment in their prior therapy, Calithera said.
Price: 3.48, Change: +0.13, Percent Change: +3.73
http://www.mtnewswires.com Copyright © 2016 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
(0)
(0)